Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Any Cancer Clear all
Active, not recruiting Phase 1 Interventional

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

NCT04521686
View directory record Official record
Conditions
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Interventions
LY3410738, Gemcitabine, Cisplatin, Durvalumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

COVID-19 and Cancer Consortium Registry

NCT04354701
View directory record Official record
Conditions
COVID-19, Invasive Malignancy (Any Type)
Interventions
Web-based REDCap survey
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19,275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Novel Optical Surface Image Guidance System for Beam-Gated Online Adaptive SBRT Delivery in Mobile Lower Lung and Upper Abdominal Malignancies

NCT05030454
View directory record Official record
Conditions
Any Solid Malignancies of Any Tissue Origin (Except for Small Cell Lung Cancer) Involving the Upper Abdomen and Thorax
Interventions
ETHOS, CT-guided stereotactic adaptive radiotherapy
Device · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

NCT00506779
View directory record Official record
Conditions
Uterine Cancer
Interventions
Imatinib Mesylate, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Not applicable Interventional Results available

Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients

NCT01169753
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Placebo, Armodafinil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional

NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)

NCT00248404
View directory record Official record
Conditions
Tumors
Interventions
NB1011
Drug
Lead sponsor
Kiadis Pharma
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Los Angeles, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 23, 2026, 10:35 PM EDT
Not yet recruiting Phase 2 Interventional

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events

NCT07836101
View directory record Official record
Conditions
Any Advanced Solid Tumors
Interventions
Sarilumab, ICI Therapy
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

NCT00920868
View directory record Official record
Conditions
Solid Tumor, Metastatic Colorectal Cancer
Interventions
dasatinib, bevacizumab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Denver, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 23, 2026, 10:35 PM EDT
Completed No phase listed Observational

Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma

NCT00588198
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 23, 2026, 10:35 PM EDT
Withdrawn Phase 2 Interventional

Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination

NCT00712621
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Counseling, Written materials
Behavioral
Lead sponsor
American Scitech International
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Englishtown, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Erlotinib and Temsirolimus for Solid Tumors

NCT00770263
View directory record Official record
Conditions
Solid Tumors
Interventions
Erlotinib, Temsirolimus
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 2Phase 3 Interventional

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

NCT00127387
View directory record Official record
Conditions
Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Interventions
Enbrel
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

NCT02875548
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epitheliod Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Santa Fe, California • Port Saint Lucie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional

Optimization for Regorafenib in HCC

NCT04476329
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Regorafenib 40 MG
Drug
Lead sponsor
SC Liver Research Consortium, LLC
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
9
States / cities
Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

NCT01804530
View directory record Official record
Conditions
Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
Interventions
PLX7486 TsOH
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study to Determine if Tissue Scored With a Scalpel Results in Any Noticeable Marks

NCT00367042
View directory record Official record
Conditions
Skin Cancer
Interventions
Scalpel for tissue scoring, Surgical marker for tissue marking
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 23, 2026, 10:35 PM EDT
Completed No phase listed Observational

Registry Study for Talimogene Laherparepvec

NCT02173171
View directory record Official record
Conditions
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
Interventions
Information collection
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
26
States / cities
Mobile, Alabama • Little Rock, Arkansas • Santa Rosa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Not applicable Interventional Results available

Compassionate Same-Day Evaluation & Delivery of XRT for Bony Metastasis in Hospice Patients

NCT01760941
View directory record Official record
Conditions
Symptomatic Osseous Bone Lesions From Any Malignancy
Interventions
Radiation Therapy, Quality-of-Life Assessment, Survey Administration
Radiation · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

NCT01942135
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
134
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 23, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional

A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer

NCT06984861
View directory record Official record
Conditions
Oropharyngeal Carcinoma
Interventions
18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires
Diagnostic Test · Combination Product · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma

NCT00430261
View directory record Official record
Conditions
Lung Cancer, Adenocarcinoma
Interventions
sunitinib
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Sep 23, 2026, 10:35 PM EDT
Withdrawn Phase 2 Interventional

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

NCT03901378
View directory record Official record
Conditions
Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, High Grade Neuroendocrine Carcinoma, Any Site
Interventions
Pembrolizumab
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Kenner, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 23, 2026, 10:35 PM EDT
Active, not recruiting Phase 3 Interventional

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
30
States / cities
Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

NCT03689855
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC
Interventions
Ramucirumab, Atezolizumab, Peripheral blood draw, Biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 23, 2026, 10:35 PM EDT